FONT-SIZE Plus   Neg

Watson Laboratories Files ANDA To Market Nebivolol Hydrochloride Tablets

Watson Laboratories Inc., a subsidiary of Watson Pharmaceuticals Inc. (WPI), has filed an Abbreviated New Drug Application with the FDA seeking approval to market Nebivolol Hydrochloride Tablets, the generic version of Forest Laboratories' Bystolic.

Bystolic is a beta-adrenergic blocking agent that is approved for the treatment of hypertension.

Forest Laboratories filed suit against Watson on March 13 in the US District Court of Delaware seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent.

Watson said it might be the first applicant to file an ANDA for the generic version of Bystolic and if approved it will be entitled to 180 days of generic market exclusivity.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Aerospace and defense major Airbus Group SE Wednesday reported a decline in nine-month profit and new orders, while revenues were stable. The weak results reflected the ongoing ramp-up and transition from current to new aircraft models. Looking ahead, for fiscal 2016, the company continues to expect stable adjusted earnings per share and EBIT. Apple Inc. (AAPL) reported its third straight quarter of iPhone sales and revenue declines after the market closed on Tuesday. The tech giant's fourth-quarter profit trumped Wall Street expectations, while revenues fell short. Although, Apple reported its third straight year-over-year decline in iPhone... Buick, Lexus and Toyota are among the top brands with highest reliability rating in the latest annual brand reliability survey.
comments powered by Disqus
Follow RTT